环磷腺苷-葡甲胺治疗慢性肺心病心肺功能不全多中心临床研究

目的观察环磷腺苷-葡甲胺(心先安)治疗慢性肺心病心肺功能不全的临床疗效.方法将785例慢性肺心病患者分为观察组和对照组,两组常规治疗相同,观察组加用环磷腺苷-葡甲胺注射液,疗程5～10d.比较两组治疗后临床症状、体征、心电图、肺通气功能和动脉血气的改善程度.结果观察组和对照组的临床症状和体征改善的有效率分别为92.2%和73.6%;肺活量(VC)较治疗前分别增加(426±123)ml和(313±145)ml;一秒钟用力呼气量(FEV1)分别增加(134±54)ml和(95±55)ml;最大呼气流量(PEF)分别增加(0.78±0.32)L/s和(0.47±0.32)L/s;动脉血氧分压(PaO2)分别增加(23.4±9.5)mmHg和(17.3±10.4)mmHg;心电图有效率分别为63.7%和41.2%,两组比较差异有非常显著性(P＜0.01,P＜0.05).结论联合使用环磷腺苷-葡甲胺治疗慢性肺心病心肺功能不全有显著疗效.

A multicenter clinical study on clinical effects of meglumine cyclic adenylate in treating patients with chronic pulmonary heart disease

OBJECTIVE: To observe the clinical effects of meglumine cyclic adenylate (MCA) in treating patients with chronic pulmonary heart disease. METHODS: 785 patients with chronic pulmonary heart disease were divided into two groups: MCA group and control group. Both groups of patients were treated with the same ordinary methods, but MCA was given in the MCA group. The period of treatment was 5-7 days. The degree of improvement in clinical symptoms, signs, ECG, pulmonary ventilation function and arterial blood gas analysis of the two groups before and after treatment were compared. RESULTS: The rates of improvement in clinical symptoms and signs were 92.2% and 73.6% in MCA group and control group respectively. VC increased (426 +/- 123) ml and (313 +/- 145) ml respectively as compared with the values before the treatment. FEV(1) increased (134 +/- 54) ml and (95 +/- 55) ml, PEF increased (0.78 +/- 0.32) L/s and (0.47 +/- 0.32) L/s and PaO(2) increased (23.4 +/- 9.5) mm Hg and (17.3 +/- 10.4) mm Hg respectively. The rates of ECG improvement were 63.7% and 41.2% respectively. There was significant difference between the two groups (P < 0.01 and 0.05). CONCLUSION: Significant therapeutic effects were obtained in treating patients of chronic pulmonary heart disease with respiratory and cardiac failure by using ordinary treatment measures combined with MCA injection.